Want to see CH:SHLTN full AI Analyst Report?
Top Page
Shl Telemedicine
(SHLTN)
Select Model
Select Model
Rating:46Neutral
Price Target:
CHF1.00
Action:Reiterated
Date:09/30/26
The score is primarily held down by weak financial performance, driven by persistent net losses and consistently negative free cash flow. Technical indicators are broadly neutral with only modest support from price trends, while valuation remains constrained due to negative earnings and no dividend information.
Positive Factors
Return to Revenue Growth
The return to 8.2% revenue growth in 2025 indicates renewed demand or improved commercial execution after a period of stagnation. If maintained, expanding revenue can improve operating leverage, support investment in telehealth capabilities, and provide a stronger base for eventual profitability.
Negative Factors
Persistent Net Losses
Persistent and deep net losses weaken earnings quality and reduce the company’s ability to reinvest from internally generated profits. Continued losses can also erode equity over time, constrain strategic flexibility, and make a durable improvement in shareholder returns dependent on a successful profitability turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Return to Revenue Growth
The return to 8.2% revenue growth in 2025 indicates renewed demand or improved commercial execution after a period of stagnation. If maintained, expanding revenue can improve operating leverage, support investment in telehealth capabilities, and provide a stronger base for eventual profitability.
Read all positive factors
Shl Telemedicine (SHLTN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF39.65M
Dividend Yield17.14%
Average Volume (3M)3.46K
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue Growth-0.04%
EPS Growth46.39%
CountryCH
Employees526
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.55
Shares Outstanding37,059,944
10 Day Avg. Volume5,236
30 Day Avg. Volume3,459
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.73
Price to Sales (P/S)0.52
P/FCF Ratio-9.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shl Telemedicine Business Overview & Revenue Model
Company Description
Established in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. is a global provider specializing in the development and distribution of individual remote healthcare solutions across Israel, Europe, and other international markets...
How the Company Makes Money
null...
Shl Telemedicine Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
60
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.81M | 61.49M | 56.78M | 57.08M | 59.00M | 49.58M |
| Gross Profit | 28.40M | 22.89M | 25.79M | 25.26M | 27.19M | 24.59M |
| EBITDA | 4.00M | 3.28M | -18.15M | 3.02M | 9.48M | 4.35M |
| Net Income | -15.00M | -16.11M | -28.09M | -7.06M | -76.00K | -14.11M |
Balance Sheet | ||||||
| Total Assets | 83.61M | 84.56M | 80.76M | 113.05M | 110.78M | 129.59M |
| Cash, Cash Equivalents and Short-Term Investments | 19.38M | 25.26M | 17.52M | 26.25M | 18.70M | 32.06M |
| Total Debt | 10.75M | 13.08M | 16.12M | 19.86M | 26.74M | 32.50M |
| Total Liabilities | 40.29M | 40.82M | 41.51M | 36.59M | 51.49M | 68.83M |
| Stockholders Equity | 43.32M | 43.74M | 39.25M | 73.53M | 55.69M | 56.85M |
Cash Flow | ||||||
| Free Cash Flow | -2.22M | -3.48M | -4.04M | -6.99M | -1.73M | -3.07M |
| Operating Cash Flow | -869.38K | -1.90M | -372.00K | -1.50M | -73.00K | 185.00K |
| Investing Cash Flow | -5.93M | 7.93M | 6.03M | -9.35M | -6.43M | -40.97M |
| Financing Cash Flow | 6.77M | 11.02M | -4.87M | 13.67M | -2.28M | 51.08M |
Shl Telemedicine Technical Analysis
Negative
―
Price Trends
1.06
Negative
1.02
Positive
1.05
Positive
Market Momentum
>-0.01
Negative
49.43
Neutral
85.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:SHLTN, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 1.05, equal to the 50-day MA of 1.06, and equal to the 200-day MA of 1.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.43 is Neutral, neither overbought nor oversold. The STOCH value of 85.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:SHLTN.
Shl Telemedicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Shl Telemedicine Corporate Events
SHL Telemedicine Faces Class Action Motion Over Subscription Pricing
Sep 24, 2026
SHL Telemedicine has disclosed that it received a motion seeking certification of a class action lawsuit alleging that the company charged excessive monthly subscription fees and implemented price increases in violation of service agreements and c...
SHL Telemedicine Shareholders Approve Opting-Out Provision on Takeover Offers
Sep 17, 2026
SHL Telemedicine Ltd. reported that shareholders at a Special General Meeting approved the inclusion of an opting-out clause in the company’s Articles of Association under Swiss financial market law. The new provision states that any party c...
SHL Telemedicine Pays Additional NIS 2.6 Million in Mediton and Medishur Deal Dispute
Sep 15, 2026
SHL Telemedicine Ltd. has confirmed the payment of an additional NIS 2.6 million, about USD 0.8 million, in indexation differentials and interest related to its purchase of stakes in Mediton Medical Centers Chain Ltd. and Medishur Ltd. The payment...
SHL Telemedicine Tightens Grip on Israeli Medical Centers With Mediton and Medishur Buyout
Sep 9, 2026
SHL Telemedicine has expanded its footprint in Israeli healthcare services by completing the purchase of an additional 27.5% stake in Mediton Medical Centers Chain and the remaining 30% of Medishur, for a total consideration of about NIS 28.9 mill...
SHL Telemedicine Narrows Loss as Efficiency Gains Lift First-Half 2026 Results
Sep 9, 2026
SHL Telemedicine reported improved first-half 2026 results, with revenue rising 12% year-on-year to USD 31.3 million and adjusted EBITDA more than doubling to USD 1.8 million. Net loss narrowed to USD 3.9 million as cost-reduction measures and ope...
SHL Telemedicine Seeks Opt-Out From Swiss Mandatory Tender Offer Rules
Aug 25, 2026
SHL Telemedicine has called a Special General Meeting for September 17, 2026, where shareholders will vote on adding an opting-out clause to its articles of association under Swiss takeover law. The change would exempt investors surpassing 33͕...
SHL Telemedicine to Fully Acquire Remaining Stakes in Israeli Subsidiaries After Court Ruling
Aug 24, 2026
SHL Telemedicine has received a judgment from the District Court in Israel requiring it to pay the full consideration for the remaining 30% stake in its subsidiaries Mediton Medical Centers Chain and Medishur. The court confirmed that SHL’s ...
SHL Telemedicine Shareholders Approve Governance and Executive Option Changes at 2026 AGM
Jul 16, 2026
SHL Telemedicine has reported the results of its 2026 Annual General Meeting held in Tel Aviv, where shareholders approved several key governance and compensation measures. The company confirmed the reappointment of Kost Forer Gabbay Kasierer, a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.